About Worldwide  |     FAQs    |    Careers    |        Media Center  |    Taj Pharmaceuticals |  World   |    TAJ Group
    © 2004 - 2009 Taj Pharmaceuticals Limited . All rights reserved rationale for the demerger of the R&D company
       India              Latin America/ Caribbean            Africa & Middle East              Asia              Russia              Europe  

Active Pharmaceutical Ingredient
   
   PRODUCT LIST
   Home
   API
   Pharmaceuticals API List
   Chemicals
   Manufacturing
   Product Development
   Product Search
   Agro Chemicals
   Custom Pharma Services
   Contact Us
 
API manufacturing factories in India



 



 

 

 
HOME >> FAQs

What is the rationale for the demerger of the R&D company?

The R&D company will have projects in the areas of new molecule and novel drug delivery systems, projects that will earn intellectual property and
revenues from international markets. The rationale for the demerger is to allow the right focus and resource commitment for long term projects that
have a different timeframe to completion.


Q-6. What are the current projects in NCE and NDDS research?

The details of the current projects will be shared a month prior to the listing of the new company. The NDDS projects are on four platforms- CR/SR,
DPI, biodegradable membranes and targeted drug delivery. The NCE projects follow a therapeutic analogue based approach in areas of known
biology.


Q-7. How many factories are USFDA approved? How many factories are in the US?

Two API manufacturing factories in India, in Panoli and Ahmednagar, hold USFDA approval. Three dosage form plants in the US- Detroit (Caraco),
and plants at Bryan, Ohio and at Cranbury hold or will be shortly submitted for USFDA approval. One dosage form plant in India, in Halol, holds
USFDA approval, for tablets, injectables and nasal sprays.


Q-8. How many people work at Taj Pharmaceuticals Ltd.? How many people are in marketing?
How many people are in research?


Across the group, including subsidiaries, over 5,000 people work at Taj Pharmaceuticals Ltd.. About 500 people work in marketing and sales in India,
and 260 in international markets (other than the US). About 500 scientist work in research.


What is the breakdown by type of business?

We are predominantly a dosage form company, with 84% of sales from prescription products. APIs account for 16% of sales.
Domestic formulations, the sale of speciality prescription brands in India, account for about 55% of sales. International markets are about 40% of sales.
of this, the US generic business at Caraco is 22%. (For the year ending March 31, 2006)

Q-10. What are the company's capex plans?

Typically Rs. 1,000 million are invested every year in capacity expansion at the current sites. This is in addition to the Rs. 2,000 million we invest
annually, at 10-12% of turnover, in R&D.


Taj Pharmaceuticals API Logo

taj group

FAQs

Copyright © Taj Pharmaceuticals Ltd. | Privacy Policy | Terms & Conditions | Sitemap

Investor Relations    Feedback     Contact Worldwide    Sitemap

 

taj group logo
Active Pharmaceutical Ingredients manufacturer, exporter, drug ingredients, pharmaceuticals, India
© 2004 - 2009
Taj Pharmaceuticals Limited . All rights reserved
Note:-We are committed to helping you find the right answers to your questions and concerns. However, this web site is not intended to give investment advice, promote the use of Taj Pharmaceuticals  Ltd products or provide information on which to base medical treatment. If you have questions regarding any Taj Pharmaceuticals  Ltd product or are experiencing a medical emergency, please consult your health care provider.
Additionally, contact information on this web site cannot be used to report adverse drug events. If you are a physician, please follow the procedures required by your country's regulations. Please choose one of the given options to contact us and we will respond to your inquiry as quickly as possible.